Document is current
Any future updates will be listed below
-
Authors
Preusser, Matthias https://orcid.org/0000-0003-3541-2315
Kazda, Tomáš
Le Rhun, Emilie
Sahm, Felix
Smits, Marion
Gempt, Jens
Koekkoek, Johan AF
Monti, Angelo F
Csanadi, Marcell
Pitter, János György
Bulbek, Helen
Fournier, Beatrice
Quoilin, Caroline
Gorlia, Thierry
Weller, Michael
Minniti, Giuseppe
,
-
Funding
Funding for this research was provided by:
Horizon 2020 Framework Programme (101103655)
- License Information
-
More Information
Article History
Received: 2 May 2024
Accepted: 30 May 2024
First Online: 7 June 2024
Declarations
:
: Ethical approval is assigned by all participating sites before patients’ enrollment. All participating patients will provide written informed consent. Informed consent will be collected by the local investigators, who are board-certified physicians with current good clinical practice (GCP) certification, and confirmed delegation and completed training for clinical trial activities.
: This manuscript does not contain individual personal data from patients. No identifying images or other personal or clinical details of participants are presented here or will be presented in reports of the trial results. The participant information materials and informed consent form are available from the authors on request and after relevant contractual arrangements.
: MP has received honoraria for lectures, consultation, or advisory board participation from the following for-profit companies: Bayer, Bristol-Myers Squibb, Novartis, Gerson Lehrman Group (GLG), CMC Contrast, GlaxoSmithKline, Mundipharma, Roche, BMJ Journals, MedMedia, Astra Zeneca, AbbVie, Lilly, Medahead, Daiichi Sankyo, Sanofi, Merck Sharp & Dome, Tocagen, Adastra, Gan & Lee Pharmaceuticals, Janssen, Servier, Miltenyi, Böhringer-Ingelheim, Telix, and Medscape.JG has received honoraria for lectures, consultation, or advisory board participation from the following for-profit companies: Zeiss and Saegen.JK: the author declares that he has no competing interests.TK: the author declares that he has no competing interests.FS: Honoraria from Illumina and co-founder and shareholder of Heidelberg Epignostix GmbHTG, BF, and CQ (EORTC): the authors declare that they have no competing interests.TGO: the author declares that he has no competing interests.ELR has received research grants from Bristol Meyers Squibb (BMS), and honoraria for lectures or advisory board participation or consulting from Bayer, Janssen, Leo Pharma, Pierre Fabre, Roche, Seattle Genetics, and Servier.MW has received research grants from Novartis, Quercis, and Versameb and honoraria for lectures or advisory board participation or consulting from Anheart, Bayer, Curevac, Medac, Neurosense, Novartis, Novocure, Orbus, Pfizer, Philogen, Roche, and Servier.
